Research and Clinical Trials

Brief Description  
This is a Phase III randomized, placebo-controlled, double-blind study that will evaluate the effectiveness of the HMG-CoA reductase inhibitor rosuvastatin in preventing the occurrence of adenomatous polyps of the colon or rectum, metachronous colorectal carcinoma and colon cancer recurrence (APMC+R) among colon cancer patients treated for cure. Eligible patients will be stratified according to family history of a first-degree relative with colorectal cancer, intended aspirin dose and adjuvant
Who may be Eligible  

  • Patients must be =18 years old
  • Patients must have an ECOG performance status of 0 or 1
  • Patients must have the ability to swallow oral medication
  • Patients must have resected adenocarcinoma of the colon stage as AJCC Stage I or II
  • Patients must have had surgical resection of the colon adenocarcinoma with curative intent within 1 year prior to randomization. Laparoscopically-assisted colectomy is permitted
  • Patients must have completed any adjuvant therapy prior to randomization
IRB Number  
Principal Investigator  
Salmon, Stuart

For More Information, Contact  Delois  , DeShazo
Phone:  (704) 355-1342  Fax:  (704) 355-1353  
Address:1100 South Tryon Street Suite 220 Charlotte, NC 28203